Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 66.8383
- Book/Share 17.8792
- PB 18.1026
- Debt/Equity 5.6749
- CurrentRatio 1.2797
- ROIC 0.1044
- MktCap 174284653976.0
- FreeCF/Share 21.448
- PFCF 15.104
- PE 24.8578
- Debt/Assets 0.6056
- DivYield 0.029
- ROE 0.9619
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Amgen Stock: New All-Time Highs Ahead After Earnings Beat
Published: November 07, 2025 by: MarketBeat
Sentiment: Positive
Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.
Read More
Stock Of The Day: Will Amgen Reverse Again?
Published: November 06, 2025 by: Benzinga
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings.
Read More
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Read More
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth. AMGN delivered strong Q3 results, with double-digit revenue and volume growth across key segments, and maintains an attractive 3.2% dividend yield. Valuation metrics remain favorable, and management's focus on R&D and operating margins positions AMGN to capture expanding therapeutic markets.
Read More
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
Published: October 31, 2025 by: PRNewsWire
Sentiment: Neutral
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events THOUSAND OAKS, Calif. , Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA.
Read More
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Read More
5 Best Dividend Stocks in the Nasdaq Composite
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Positive
What's the first thing that springs to mind when someone mentions the Nasdaq Composite?
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Why Amgen (AMGN) Could Beat Earnings Estimates Again
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Published: October 07, 2025 by: CNBC
Sentiment: Positive
Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.
Read More
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
Published: October 06, 2025 by: WSJ
Sentiment: Negative
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Amgen to sell cholesterol drug at 60% discount direct to US consumers
Published: October 06, 2025 by: Reuters
Sentiment: Neutral
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressure to lower drug prices.
Read More
Amgen Shares Cross Above 200 DMA
Published: October 01, 2025 by: Forbes
Sentiment: Positive
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
Published: September 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they offer a significant income stream and have massive total return potential.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
Read More
Amgen: Imdelltra Could Be The Next Game Changer
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Positive
Despite the political noise coming out of the White House over efforts to lower drug prices, Amgen Inc.'s oncology franchise has continued to deliver strong performance since the start of 2025. So, AMGN's sales of Imdelltra, which is rapidly capturing the lung cancer therapeutics market, reached $134 million in Q2 2025, an impressive 1016.7% increase year-over-year. Also, thanks to the synergy effects from the acquisition of Horizon, as well as growing demand for Blincyto, AMGN's gross profit margin reached 70.9%, 9.5% higher than in Q2 2024.
Read More
Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000